My “top 3” takeaways from ACC23 are;
CLEAR Outcomes trial which demonstrated that bempedoic acid reduced LDL by about 20% and improves long-term CV outcomes compared with placebo among patients with established ASCVD or high risk for it, and intolerance to statin therapy (though a minor...
3 major trials in structural heart disease were presented at ACC:
TRILUMINATE RCT of medical therapy vs transcatheter edge-to-edge repair in patients with severe symptomatic tricuspid regurgitation. A key finding is that transcatheter repair was (a) effective in reducing tricuspid regurgitation (87...